Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Tieshi Zhu: NHANES Study Reveals Significant Mortality Risk With Clopidogrel Monotherapy After PCI
Platelets Journal/LinkedIn
Aug 23, 2025, 08:01

Tieshi Zhu: NHANES Study Reveals Significant Mortality Risk With Clopidogrel Monotherapy After PCI

Platelets Journal shared an insightful post on LinkedIn:

“How does clopidogrel monotherapy compare to aspirin after PCI and DAPT?

Building on a recent Korean study that highlighted the efficacy of clopidogrel monotherapy following percutaneous coronary intervention (PCI) and standard dual antiplatelet therapy (DAPT), Zhu et al. (2025) conducted a retrospective analysis of the U.S. NHANES 1999–2018 cohort to compare all-cause mortality between clopidogrel and aspirin monotherapy under similar conditions.

Contrary to previous findings in Asian populations, the authors found that clopidogrel monotherapy was associated with increased risks of all-cause mortality, cardiac mortality, and stroke compared to aspirin monotherapy.”

Read the full article here:

Article: Clopidogrel monotherapy is associated with higher mortality risk compared to aspirin: a retrospective analysis of NHANES 1999–2018

Authors: Tieshi Zhu, Yong He, Yuzhang Bei, Hui Mai, and Le Zhao

Tieshi Zhu: NHANES Study Reveals Significant Mortality Risk With Clopidogrel Monotherapy After PCI

Follow the newest developments in clotting science with Hemostasis Today.

Antiplatelet Therapy Aspirin cardiology research cardiovascular outcomes clopidogrel DAPT Hui Mai and Le Zhao Mortality NHANES PCI platelets Platelets Journal retrospective analysis secondary prevention stroke Tieshi Zhu Yong He Yuzhang Bei
NewsFeed